Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy.

Trial Profile

Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 May 2017

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Expanded access
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 17 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top